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Acute lymphoblastic leukemia (ALL) accounts for approximately 75% of childhood leukemia, and chemotherapy remains the
mainstay therapy. Baicalein is an active �avonoid used in traditional Chinese medicine and has recently been found to have
anticancer, anti-in�ammatory, and antiallergic properties. is study aims to investigate the molecular apoptotic mechanisms of
baicalein in CCRF-CEM leukemic cells and to evaluate the combined therapeutic eﬃcacy of baicalein with several commonly used
chemotherapeutic drugs in CCRF-CEM cells. Our results demonstrate that baicalein induces mitochondria-dependent cleavage of
caspases-9 and -3 and PARP with concomitant decreases in IAP family proteins, survivin, and XIAP. Furthermore, our results
present for the �rst time that baicalein triggers a convergence of the intrinsic and extrinsic apoptotic pathways via the death
receptor-caspase �-tBid signaling cascade in CCRF-CEM cells. In addition, we also present for the �rst time that the combination of
baicalein and vincristine results in a synergistic therapeutic eﬃcacy. Overall, this combination strategy is recommended for future
clinical trials in the treatment of pediatric leukemia owing to baicalein�s bene�cial eﬀects in alleviating the vomiting, nausea, and
skin rashes caused by chemotherapy.
1. Introduction
Leukemia is oen described as acute or chronic. Acute refers
to the relatively short time course of the disease (being lethal
in as little as a few weeks if le untreated) to distinguish
it from the very diﬀerent disease of chronic lymphocytic
leukemia, which has a potential time course of many years.
Almost all childhood leukemia is acute. Acute lymphocytic
(lymphoblastic) leukemia (ALL) accounts for approximately
75% of childhood leukemia.e treatment of childhood ALL
consists of a combination of several anticancer drugs and
is usually divided into the following 3 phases: induction,
consolidation (also called intensi�cation) and maintenance
[1]. Vincristine and methotrexate are two drugs commonly
used to treat childhood ALL that can be used in all 3 phases
of treatment [1]. Depending on the therapy dose, most
chemotherapeutic agents have side eﬀects, such as diarrhea,
nausea, vomiting, and skin rashes. For example, vincristine
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has additional peripheral neurological side eﬀects such as
hearing changes, sensory loss, numbness, and tingling. Seri-
ous side eﬀects in response to chemotherapeutic agents
prompt researchers and clinicians to seek novel anticancer
agents that have fewer side eﬀects, and these newly explored
anticancer agents can be used in combination with the
commonly used chemotherapeutic agents to reduce serious
side eﬀects.
Baicalein, extracted from the root of Scutellaria baicalen-
sis, is an active �avonoid that has been found to have
anticancer properties [2–4]. Baicalein inhibits cancer cell
proliferation and induces apoptosis of human gastric cancer
cell lines [5]. In an in vivo experiment, mice were injected
with bladder cancer cells with concurrent oral administration
of a high-baicalein-yielding supplement in one group or
with no baicalein supplementation in the control group.
All the control mice had a progressive increase in the
tumor volume over the ensuing days of the study, whereas
the mice treated with baicalein (Scutellaria) had signi�cant
inhibition of the tumor growth [6]. Other studies testing
baicalein as an antitumor agent support its potential use in
breast and prostate cancers [7–9]. Baicalein has been found
to selectively induce apoptosis in human cancer cell lines
with minimal in�uence on noncancer cells [10–12]. In fact,
Scutellaria baicalensis has been used in traditional Chinese
medicine to treat a variety of medical conditions including
diarrhea, vomiting, nausea, asthma, gout, and in�ammatory
conditions, such as dermatitis, arthritis, bronchitis, and
in�ammatory bowel disease [2]. Although baicalein is found
to induce apoptosis in several types of cancers, the molecular
apoptotic mechanisms of baicalein and the combined eﬀects
of baicalein with other commonly used chemotherapeutic
drugs on childhood acute lymphoblastic leukemia CCRF-
CEM cells have not previously been investigated.
In the present study, we aimed to investigate the
molecular apoptotic eﬀects and mechanisms of baicalein
on CCRF-CEM leukemic cells and evaluate the combined
therapeutic eﬃcacy of baicalein with other commonly used
chemotherapeutic drugs on CCRF-CEM leukemic cells. We
found that baicalein induces apoptosis primarily through the
mitochondria-dependent activation of the caspase-9 and -3
pathways. Moreover, we demonstrated for the �rst time that
baicalein induces the activation of the death receptor-caspase
8-tBid signaling cascade, which converges with the intrinsic
pathway at the mitochondrial level. More importantly, we
found a synergistic therapeutic eﬀect when baicalein and
vincristine were used in combination.
2. Material andMethods
2.1. Chemicals and Reagents. Baicalein (Sigma-Aldrich,
St. Louis, MO) was 98% pure. A 100mM stock solution of
baicalein was prepared, and this solution was subsequently
diluted to 6.25–100 𝜇𝜇M in DMSO. Vincristine (Sigma-
Aldrich, St. Louis, MO) was >95% pure. A 100-𝜇𝜇M stock
solution of Vincristine was prepared, and this solution was
subsequently diluted to 1.25–5 nM in DMSO. MTT, 3-
(4,5-dimethylthiazoly1-2)-2,5-diphenyltetrazoliumbromide,
Dantrolene dimethyl sulfoxide (DMSO), propidium iodide
(PI), and Triton X-100 were purchased from Sigma. RPMI
Media 1640, fetal bovine serum (FBS), and trypsin-EDTA
were obtained fromGibco.e JC-1Assaywas obtained from
Molecular Probes. Inhibitors of caspase-3 (Ac-DEVD-CMK),
caspase-8 (Z-IETD-FMK), and caspase-9 (Z-LEHD-FMK)
were obtained from Calbiochem and were dissolved in
DMSO.
2.2. Cell Culture. e human childhood leukemia cell line
(CCRF-CEM) was purchased from ATCC. e cells were
grown in RPMI 1640 medium (GIBCO) with 20% fetal
bovine serum (FBS; GIBCO) at 37∘C in a humidi�ed incu-
bator containing 5% CO2.
2.3. Antibodies. Antibodies against Bcl-2 and Bax were pur-
chased from Santa Cruz. An antibody against Cytochrome c
was purchased from BD PharMingen. Antibodies speci�c for
cleaved caspases-3, -8, and -9, truncated Bid, XIAP, cleaved
PARP, and Survivin were purchased from Cell Signaling.
An anti-𝛽𝛽-actin antibody was purchased from Sigma. Anti-
mouse and -rabbit IgG peroxidase-conjugated secondary
antibodies were purchased from Jackson ImmunoResearch
Laboratory.eDR4, DR5, Fas, TRAIL, FasL antibodies used
in �ow cytometry were obtained from eBioscience.
2.4. Cytotoxicity Assay. e cytotoxic eﬀect of baicalein
on CCRF-CEM cells was measured by the 3-[4,5-dimeth-
ylthiazol-2-yl]-2,5 diphenyltetrazolium (MTT) assay (Sigma-
Aldrich, St. Louis, MO). CCRF-CEM cells were seeded onto
24-well plates for 24 h. Various concentrations of baicalein
were added to the cells, followed by 24 h and 48 h of
incubation.en, themediumwas removed, and 200𝜇𝜇L of 1x
MTT solution was added to each well for 4 h.e absorbance
at 540 nmwas determined via a microplate reader (TECAN).
e half maximal inhibitory concentration (IC 50) of the
drug was calculated by polynomial regression analysis using
Microso Excel soware.
2.5. Annexin V Assay. An apoptosis assay was conducted
with the BioVisionAnnexinV-FITCApoptosisDetectionKit.
Leukemia CCRF-CEM cells were seeded onto a 6-cm dish for
24 h and then exposed to diﬀerent doses of baicalein for 24 h.
Cells were harvested and washed twice with PBS and then
resuspended in 500 𝜇𝜇L of binding buﬀer. Cell suspensions
were then incubatedwith 5 𝜇𝜇L of annexinV-FITC and 5 𝜇𝜇L of
propidium iodide (PI) for 10min at room temperature in the
dark.e cells were immediately evaluated by �ow cytometry
(FACSCalibur, BD BioSciences).
2.6. Cell Cycle Analysis. 3 × 105 cells were plated onto
a 6 cm dish for 24 h. e cells were then treated with
diﬀerent concentrations of baicalein for 24 h, followed by cell
collection with centrifugation. e pellets were mixed with
75% ethanol at −20∘C overnight. e cells were centrifuged
and resuspended in 500 𝜇𝜇L of PI staining solution (2mg/mL
RNase, 1mg/mL PI and 0.5% Triton X-100) for 1 h at
37∘C in the dark. e cells were then analyzed by FACS
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Calibur �ow cytometry (BD Biosciences). e distribution
and percentages of cells in the sub-G1, G0/G1, S, and G2/M
phases of the cell cycle were analyzed usingWinMDI soware
(Scripps Research Institute, La Jolla, CA).
2.7. Measurement of the Reactive Oxygen Species (ROS)
by Flow Cytometry. ROS production was measured aer
staining the cells with 5-(and-6)-carboxy-2′,7′-dichlorodi-
hydro�uorescein diacetate (DCFDA� Molecular Probes).
Additionally, 3 × 105 CCRF-CEM cells/dish were plated onto
a 6-cm tissue culture dish with 3mL ofmedium.emedium
was removed 12 and 24 h aer baicalein treatment, and
culture medium containing 5 𝜇𝜇M DCFDA was added under
low-light conditions. e cells were incubated for 30min at
37∘C, and the ROS level was measured by �ow cytometry
(FACSCalibur, BD BioSciences).
2.8. Western Blot Analysis. Whole cells were lysed in 2% SDS
containing 10mMEDTA, 50mMTris base, 10% SDS, pH 8.0,
and boiled at 100∘C for 10 minutes. Protein concentrations
were measured by a BCA Protein Assay. Equal amounts of
protein were loaded into 10%–15% SDS-PAGE gels, trans-
ferred to PVDF membranes and blocked with 5% non-fat
milk in TBST buﬀer (20mM Tris-HCl, 120mM NaCl, and
0.1% Tween 20) for 1 hour. Membranes were incubated with
various primary antibodies. Aer washing, the blots were
incubated with HRP-labeled mouse and rabbit secondary
antibodies (Jackson Lab) for 2 hours. e signals of the blots
were then developed using the enhanced chemiluminescence
(ECL) system and analyzed by the LAS3000 system (Fu�i�lm,
Tokyo, Japan). Densitometric analysis was performed with
ImageJ soware (National Institute of Health, Bethesda, MD,
USA).
2.9. Mitochondrial Membrane Potential Assay. e mito-
chondria-speci�c cationic dye JC-1 (Invitrogen, Carlsbad,
CA), which undergoes potential-dependent accumulation in
the mitochondria, was used. When the membrane potential
(ΔΨ) is below 120mV, JC-1 remains monomeric and emits
a green light (540 nm) following excitation by blue light
(490 nm). At membrane potentials higher than 120mV, JC-1
monomers aggregate and emit red light (590 nm) following
excitation by green light (540 nm). CCRF-CEM cells were
seeded onto a 6-well plate for 24 hr and were then treated
with various concentrations of baicalein for 24 h, followed by
staining with 25 𝜇𝜇M JC-1 for 30min at 37∘C. Cells were then
washed in PBS, and 10,000 cells of each sample were analyzed
by �ow cytometry (FACS Calibur, BD, USA).
2.10. Mitochondria/Cytosol Fractionation. e Mitochon-
dria/Cytosol Fractionation Kit (Biovision) was used for isola-
tion of the mitochondrial fraction from the cytosolic fraction
in mammalian cells. Cells were harvested and washed twice
with PBS and resuspended in 500𝜇𝜇L of Cytosol extraction
buﬀer mix on ice for 10 minutes. en, cells were homog-
enized by Dounce Tissue Grinder (Biovision) on ice for
30–50 passes, followed by centrifugation at 3000 rpm for 10
minutes at 4∘C. e supernatants were collected carefully,
and centrifugation was repeated again at 13000 rpm for 30
minutes at 4∘C. e �nal supernatants were collected as the
cytosolic fractions.
2.11. Caspase Inhibitor and the Antagonistic Anti-Fas Anti-
body ZB-4 Assay. e cells were seeded at 4 × 104 cells/well
in 24-well tissue culture plates. Aer 18 h, the cells were
pre-treated with inhibitors of caspase-3 (Ac-DEVD-CMK),
caspase-8 (Z-IETD-FMK), and caspase-9 (Z-LEHD-FMK)
and an antagonistic anti-Fas antibody ZB-4 (R&D) for 1 hr.
en, the cells were treated with the indicated concentrations
of baicalein for 24 hr. en, the treated cells were incubated
with 5mg/mL MTT for 4 hr at 37∘C, followed by removal of
the supernatant and developing the color by adding 600𝜇𝜇L of
DMSO to each well. e absorbance was read at 570 nm on a
microplate reader (Tecan, Durham, NC).
2.12. Transient Transfection and RNA Interference. CCRF-
CEM cells were grown to 30% to 50% con�uency in 6-well
plates and transfected with 400 pmol of FADD siRNA (Santa
Cruz) with lipofectamine 2000 reagent (Invitrogen). Cells
were harvested and reseeded 24 h aer transfection, and cell
viability was assessed by the MTT assay in the presence or
absence of baicalein.
2.13. Analysis of Death Receptors and Ligands by Flow Cytom-
etry. Analyses of the death receptor membrane expression
and death receptor ligand expression were performed by �ow
cytometry. 3 × 105 cells/dish were plated onto 6-cm tissue
culture dishes in 3mL of medium, followed by incubation
with 0, 25, 50, and 100 𝜇𝜇M of baicalein for 24 hr. Aer
trypsinizing and washing cells with PBS, the treated cells
were stained with anti-DR4-FITC, anti-DR5-FITC, anti-Fas-
FITC, anti-TRAIL-FITC and anti-FasL-FITC (eBioscience)
at 4∘C for 30–45 minutes. e protein expressions of the
treated cells were analyzed by �ow cytometry (FACSCalibur,
BD BioSciences).
2.14. Measurement of the Intracellular Free Calcium Level.
Approximately 3 × 105 CCRF-CEM cells/well were seeded
onto 6 cm culture dishes overnight. e cells were exposed
to the indicated concentrations of baicalein for 24 h. en,
the cells were harvested and washed twice with 1 × PBS
containing 1% BSA.e cells were stained with 0.5mL Fluo-
3/AM (2.5𝜇𝜇g/mL) (Sigma-Aldrich) for 30 minutes at room
temperature in the dark. e stained cells were immediately
analyzed by �ow cytometry (FACSCalibur, BD, USA).
2.15. Statistical Analysis. e results were expressed as the
mean ± SD. Statistical analyses were performed by one-
way ANOVA followed by Tukey’s post hoc test (GraphPad
Soware Inc., SanDiego, CA).𝑃𝑃 values< 0.05was considered
statistically signi�cant. In addition, a two-way ANOVA
with Bonferroni’s test (GraphPad Soware Inc., San Diego,
CA) was used to test for an interaction between baicalein
and vincristine. Results determined by this method were
validated further in CCRF-CEM cell line by an isobologram
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according to “Drug Synergism: Its Detection and Applica-
tions” reported by Tallarida [13].
3. Results
3.1. Baicalein Induces a Potent Apoptotic Eﬀect on CCRF-
CEM Leukemic Cells. To determine the eﬀect of baicalein
on cell growth, CCRF-CEM leukemic cells were challenged
with various doses of baicalein for 24 and 48 hours, and
cell viability was measured by the MTT assay. As shown in
Figure 1(a), baicalein markedly reduced the cell viability of
CCRF-CEM cells in a dose- and time-dependent manner.
e IC50 values following 24 and 48 hr of treatment were
approximately 48.63±0.78 𝜇𝜇Mand 33.43±1.948 𝜇𝜇M, respec-
tively. To clarify the type of cell death elicited by baicalein,
CCRF-CEM cells were treated with various concentrations of
baicalein and subjected to �ow cytometry analysis following
staining with Annexin V-FITC and propidium iodide (PI).
As shown in Figure 1(b), the percentages of early apoptotic
death (Annexin V+/PI−, lower right quadrant) increased in
a dose-dependent manner in CCRF-CEM cells. In addition,
the sub-G1 population also increased in a dose-dependent
manner 24 hr aer baicalein treatment (Figure 1(c)). ese
results suggest that baicalein induces apoptosis in CCRF-
CEM leukemic cells.
3.2. Baicalein TriggersMitochondrialMembrane Potential Loss
and Cytochrome c Release. Mitochondria are known to play
a central role in apoptotic signaling because the intrinsic and
the extrinsic pathways can converge at the mitochondrial
level and trigger mitochondrial membrane potential loss [14,
15]. To investigate whether mitochondria are involved in
baicalein-induced apoptosis, we used the �uorescent cationic
dye JC-1 to examine the eﬀect of baicalein on the mitochon-
drial membrane potential (Δ𝜓𝜓𝑚𝑚). As illustrated in Figure
2(a), baicalein at 24 hr caused a dose-dependent decrease
in the red �uorescence and a concomitant dose-dependent
increase in the green �uorescence in CCRF-CEM cells,
indicating that baicalein triggers a dose-dependent reduction
in Δ𝜓𝜓𝑚𝑚. Cytochrome c release from the mitochondria into
the cytosol is an important event for apoptosis induction
following loss of Δ𝜓𝜓𝑚𝑚 [16]. erefore, we examined the
cytosolic fraction of CCRF-CEM cells with western blotting
aer 24 hr of baicalein exposure. As shown in Figure 2(b),
baicalein caused a dose-dependent elevation in cytochrome
c expression. ese results verify that the mitochondria are
involved in baicalein-induced apoptosis.
3.3. Baicalein Induces Apoptosis Primarily via the Mitochon-
drial Pathway in CCRF-CEM Leukemic Cells. Mitochondrial
dysfunction triggers subsequent activation of caspase-9 in
the presence of Apaf-1, which in turn results in the acti-
vation of downstream caspase-3 and cleavage of PARP. To
investigate the molecular events following mitochondrial
dysfunction, apoptotic related proteins were examined with
a Western blott. As shown in Figure 3(a), 24 hr of treatment
with baicalein induced a dose-dependent increase in the
cleaved/activated forms of caspase-9, caspase-3, and PARP in
CCRF-CEM cells. Treatment with the caspase-3 inhibitor Z-
DEVD and caspase-9 inhibitor Z-LEHD could rescue CCRF-
CEM cells from baicalein-induced cell death, indicating that
the caspase-dependent pathway was involved (Figure 3(b)).
In addition, Bcl-2 family proteins are frequently involved
in mitochondria dysfunction [17], and IAP family members
can mediate the inhibition of caspases-9 and -3, thereby
suppressing apoptosis [18]. As illustrated in Figure 3(c), 24 hr
of baicalein treatment resulted in signi�cant reductions of
XIAP and Survivin protein expressions. Although there was
no signi�cant change in Bcl-2 and Bax expressions, we still
observed a slight decrease in Bcl-2 and a slight increase in Bax
protein expressions. Taken together, these �ndings indicate
that baicalein induces apoptosis primarily via the intrinsic
mitochondrial pathway.
3.4. Activation of the Caspase-8-tBid Pathway in Baicalein-
Induced Apoptosis. It is well established that caspase-8 can
directly activate caspase-3 through cleavage and/or indirectly
cleave Bid (23kd) into truncated Bid (tBid), which triggers
mitochondria-dependent activation of the caspase-9 and -3
cascade [19]. To determine whether baicalein could induce
the activation of caspase 8 and its downstream Bid, CCRF-
CEM cells treated with 24 hr of baicalein were subjected
to Western blot analysis. As shown in Figure 4(a), the
cleaved caspase-8 and tBid protein levels increased aer
baicalein treatment. In addition, pretreatmentwith a selective
caspase-8 inhibitor, z-IETD-fmk, could partially rescue cell
viability (Figure 4(b)). ese data indicate that the caspase
8-tBid pathway participates in the mitochondria-mediated
apoptosis triggered by baicalein.
3.5. ROS Is Not Involved in Baicalein-Induced Apoptotic
Cell Death. Reactive oxygen species (ROS) are highly reac-
tive molecules that have been implicated in the induction
or enhancement of apoptosis [20]. A previous study sug-
gests that ROS can induce apoptosis through the caspase-
8/Bid/Bax pathway in human lymphocytes [21]. However,
baicalein is known to exhibit antioxidant eﬀects [22, 23].
erefore, we investigated whether baicalein could induce
ROS generation by means of a �uorescent probe, DCFA-
DA. As shown in Figure 5, 12 hr and 24 hr of baicalein
exposure resulted in a dose-dependent decrease inDCFA-DA
�uorescence intensity in CCRF-CEM cells, indicating that
ROS did not participate in baicalein-induced apoptosis.
3.6. Baicalein Activates the Death Receptor Pathway. Our
present study observes that baicalein can induce caspase-
8 activation. It is well established that caspase-8 activation
is associated with death receptor signaling. Six distinct
death receptors are known, including the TNF receptor-1
(TNF-R1), Fas (APO-1/CD95), TRAMP or death receptor-
3 (DR3), TRAIL receptor-1 and receptor-2 (TRAIL-R1/DR4,
TRAIL-R2/DR5), and death receptor-6 (DR6). Among them,
the TRAIL and Fas receptors and their ligands have been
extensively investigated [24]. To determine whether death
receptors were involved in baicalein-induced caspase-8 acti-
vation and apoptosis, the surface expression level of these
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death receptors was determined by �ow cytometry following
24 hr of various doses of baicalein treatment. As illustrated
in Figures 6(a) and 6(b), the Fas receptor increased signif-
icantly only aer 100 𝜇𝜇M of baicalein treatment, whereas
FasL increased signi�cantly at �0 𝜇𝜇M and elevated largely
at 100 𝜇𝜇M. Figures 6(c) and 6(d) showed that DR4 and
DR� increase signi�cantly at �0 𝜇𝜇M and increased greatly
at 100 𝜇𝜇M. Overall, these results demonstrate that the death
receptors are involved in baicalein-induced caspase-8 activa-
tion and apoptosis.
3.7. e Caspase-8 Activation-Dependent Death Receptor
Pathway Is Not the Only Trigger for the Mitochondria-
Mediated Apoptosis Induced by Baicalein. We used the Fas
neutralizing antibody ZB4 to examine whether the Fas/FasL
interaction was necessary in baicalein-induced apoptosis. As
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shown in Figure 7(a), inhibition of the ligand-binding to
Fas receptors could partially recover cell viability, indicating
that the FasL/Fas interaction was necessary here to trigger
apoptosis. Because trimerization of the Fas and TRAIL
receptors leads to recruitment of the Fas-associated death
domain (FADD), an adaptor molecule that recruits and
activates caspase-8 [25], we further used FADD siRNA
to con�rm the association of the death receptor-caspase
8-tBid and baicalein-induced mitochondrial pathways. As
illustrated in Figures 7(b) and 7(c), our results show that the
silencing of FADD could partially recover the cell viabil-
ity and repress caspase-8 activation. Overall, these results
suggest that caspase-8 activation by baicalein is mostly
dependent on death receptor signaling and that the death
receptor-caspase 8-tBid pathway participates in, but is not
the only trigger for, the mitochondria-mediated apoptosis
induced by baicalein.
3.8. Baicalein Triggers an Increase in the Intracellular Ca2+
Level. Intracellular free calcium ([Ca2+]𝑖𝑖) has been known to
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enhance apoptosis at early and later stages of the apoptotic
process [26]. In an attempt to determine whether Ca2+ plays
a role in baicalein-induced apoptosis, the intracellular Ca2+
level is measured by a Ca2+-sensitive �uorescent dye, Fluo-�
AM, following 24 hr of baicalein exposure. As illustrated in
Figures 8(a) and 8(b), baicalein caused a substantial increase
in the intracellularCa2+ at a higher dose (100 𝜇𝜇M)but seemed
to cause only slight increases at lower doses (≦50 𝜇𝜇M).
However, many apoptotic events were already quite obvious
at 50 𝜇𝜇M of baicalein treatment. is implies that Ca2+ may
enhance apoptosis at higher doses (≧100 𝜇𝜇M) of baicalein
but seems to play less important roles in apoptosis at lower
baicalein doses (≦50 𝜇𝜇M).
3.9. Combination of Baicalein and Vincristine Results in an
Enhancement in theerapeutic Eﬃcacy. Baicalein is toxic to
cancer cells but displays low cytotoxicity for human normal
cells [10]. Because vincristine can cause neurological toxici-
ties when used in high doses, the combined therapeutic eﬀect
of baicalein with moderate doses of vincristine is worthy of
investigation. Because a previous study had shown that the
IC50 of vincristine in CCRF-CEM cells was approximately
9 nM with 24 h of incubation [27], lower doses (1.25, 2.5,
Evidence-Based Complementary and Alternative Medicine 11
128
0
E
ve
n
ts
128
0
E
ve
n
ts
100 101 102 103 104
100 101 102 103 104
DCFA-DA 12 hr
0.1% DMSO
DCFA-DA 24 hr
Baicalein 100 µM
0.1% DMSO
Baicalein 50 µM
Baicalein 25µM
0.1% DMSO
M
ea
n
 f
lu
o
re
sc
en
ce
 i
n
te
n
si
ty
0
100
200
300
400
500
600
12 hr 24 hr
∗∗ ∗∗
∗∗
∗∗ ∗∗
Baicalein 25 휇M
Baicalein 50 휇M
Baicalein 100 휇M
F 5:�e eﬀect of baicalein on�OSproduction inCC�F-CEMcells. Cells were stainedwithDCFDA, followed by �ow cytometry analysis
12 h or 2� h post various concentrations of baicalein treatment.�emean �uorescence intensities for �OS generationwere tabulated.�e data
are represented as the mean ± SD in triplicate tests. Similar results were obtained in three independent experiments. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃, compared
with the untreated control group (0.1% DMSO). ∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃, compared with the untreated control group.
and 5 nM) of vincristine were combined with baicalein to
evaluate the therapeutic eﬃcacy. As shown in Figure 9(a),
our cell viability assay results demonstrate that baicalein
clearly enhances the antileukemic eﬀect of vincristine and the
combined eﬃcacy shows synergistic eﬀect. Additionally, the
enhancing eﬀect is most obvious when baicalein is combined
with moderate doses of vincristine (2.5∼5 nM). In addition,
an interaction (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃) is found between baicalein and vin-
cristine based on a two-way ANOVA with Bonferroni’s test.
Flow cytometry using annexin V��I staining also con�rmed
the enhancement in therapeutic eﬃcacy when baicalein
and vincristine were used in combination (Figure 9(b)).
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F 8:e eﬀect of baicalein on the intracellular Ca2+ concentration. (a) CCRF-CEM cells were stained with Fluo-3 AM, followed by �ow
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∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃, compared with the 0.1% DMSO control group. ∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃, compared with the 0.1% DMSO control group.
Furthermore, we preceded the cell cycle analysis in the
settings of drug-combinations at 8 h and 24 h. As shown in
Figure 9(c), the results validate that 50 𝜇𝜇Mof baicalein shows
M-phase blocking eﬀect at 8 h, and a great portion of G2-M
phase-arrested cells have died at 24 h, resulting in a decrease
in G2-M phase percentage and an increase in sub-G1 phase
percentage at 24 h. With respect to drug-combinations, the
percentage of G2-M phase under combined treatment is
much greater than baicalein or vincristine monotherapy at
8 h, and the sub-G1 percentage under combined treatment
is greater than the sum of that under each monotherapy
at 24 h. In addition, we have determined the combination
eﬀect on cell viability of baicalein and vincristine according to
“Drug Synergism: Its Detection and Applications” reported
by Tallarida [13], the resulting isobologram indicates that the
combination eﬀect of baicalein and vincristine is synergistic,
and the synergistic eﬀect is most obvious when baicalein is
combined with moderate doses of vincristine (2.5∼5 nM).
e combination eﬀect of 50 𝜇𝜇M baicalein and 1.25 nM
vincristine is more likely to be additive.
4. Discussion
In the present study, we described the cellular and molecular
events underlying baicalein-induced apoptosis in childhood
acute lymphoblastic leukemia CCRF-CEM cells. Mitochon-
drial membrane permeabilization and cytochrome c release
into the cytosol are early events in apoptotic signaling because
the intrinsic and extrinsic pathways can converge at the
mitochondrial level [14–17]. Antiapoptotic members of the
IAP family also regulate the mitochondrial pathway [18]. In
this study, our data reveal that the protein expression level
of the anti-apoptotic XIAP and Survivin was reduced 24 h
post baicalein treatment in CCRF-CEM cells (Figure 3(c)).
Caspase-8 is known to propagate the apoptotic signal by
direct cleavage and activation of downstream caspase-3 [19].
It is also well known that caspase-8 can trigger Bid cleavage
into truncated Bid, which subsequently leads to the release
of cytochrome c from the mitochondria, thereby triggering
the activation of caspase-9 [19]. Membrane death receptor
mediated apoptosis is known to be one of the pathways
leading to caspase-8 activation [24]. Upon death receptors
activation via ligation, the death receptors recruit the adapter
molecule FADD to the death domain, which is also present
on FADD, followed by activation of caspase-8 [25]. In this
study, we observed silencing of the FADD attenuated cell
death and caspase-8 activation (Figure 7(b)). In addition, we
also observed an upregulation of DR4, DR5, FasL, and Fas
(Figure 6). One previous study demonstrated that baicalein
can induce DR5 protein expression in colon and prostate
cancer cells [12]. Additional death receptors were found to
be upregulated by baicalein inCCRF-CEMcells.ese results
suggest that the cascade signaling from the Fas/Fas ligand and
DR4, DR5/TRAIL system to caspase 8-tBid plays a role in the
apoptotic killing of CCRF-CEM cells by baicalein.
Although Ca2+ is thought to be an enhancer of apoptosis,
it may not play a prominent role under the eﬃcacious dose
(50𝜇𝜇M) of baicalein that induce apoptosis in CCRF-CEM
cells. is conclusion was drawn because many apoptotic
events (mitochondrial membrane potential loss, cytochrome
c release, caspase 9, 8, 3 activation, etc.) were already quite
obvious at 50 𝜇𝜇M of baicalein treatment, but a substantial
increase in intracellular Ca2+ appeared only aer 100 𝜇𝜇M of
baicalein treatment (Figure 8). Ca2+ may participate in, but
does not seem to be the key player for, baicalein-induced
apoptosis in CCRF-CEM cells under the eﬃcacious dose of
baicalein (50 𝜇𝜇M).
In addition, 50 𝜇𝜇M of baicalein was chosen for most
of our experiments, including the combination therapy,
because the IC50 of baicalein in CCRF-CEM cells at 24 hr
is approximately 48𝜇𝜇M (Figure 1) and most of the apoptotic
events are obvious at 50 𝜇𝜇M. In addition, one previous study
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on human promyelocytic leukemia HL-60 cells also found
that an apparent reduction in cell viability was observed
only aer 24 h of 50 𝜇𝜇M of baicalein treatment [28].
Baicalein is known to be a potent anti-oxidant for
incoming oxidative stress. ere is evidence of this from
several studies; baicalein exhibited a neuroprotective eﬀect
on hydrogen peroxide-mediated oxidative stress in PC12
cells [29] and on TG- or BFA-induced ROS accumulation in
hippocampal neuronal cells [30]. Baicalein is also a potent
antioxidant against cardiomyocytes ischemia/reperfusion
injury [31]. Although increased ROS generation has been
reported in several previous studies, there may be diﬀerent
eﬀects in other cell types. is hypothesis was veri�ed in
a previous study in which 12 h aer treatment with 40𝜇𝜇M
of baicalein, the intracellular ROS level rose moderately in
PC3 prostate cancer cells, but the ROS level did not increase
in SW480 colon cancer cells [12]. Another recent study
on colon cancer cells reported �ndings that are similar to
our results; the authors found that baicalein inhibits colon
cancer cell proliferation and reduces reactive oxygen species
(ROS) [11]. ey also found that baicalein treatment has
no eﬀect on normal epithelial cells [11]. In support of this
�nding, two other studies found that baicalein hardly induces
apoptosis in normal human cells, such as blood cells and
hepatocytes [10, 12]. is phenomenon could be explained
by a recently accepted concept that antioxidants exhibiting
antiproliferative eﬀects can be lethal inmitotically active cells,
such as cancer cells but are not toxic to slow-growing non-
cancer cells [32–34]. Two important messages are delivered
here. Slow-dividing cells can easily escape from baicalein-
induced apoptosis and are even protected by the antioxidant
eﬀect of baicalein when facing oxidative stress. However,
baicalein tends to act more selectively on fast-growing cancer
cells, rendering it an eﬀective drug for cancer treatment.
Its neuroprotective eﬀects further increase its bene�ts when
combined with vincristine, which has neurotoxic side eﬀects
at higher doses.
In addition, this is the �rst report demonstrating the
apoptosis-enhancing eﬀect of baicalein when used in combi-
nationwith vincristine.is enhancement in therapeutic eﬃ-
cacy is possibly attributed to the fact that both drugs are M-
phase blockers. Vincristine inhibits cell division during early
mitosis by binding to the tubulin monomers and preventing
spindle microtubule formation. A variety of human cancer
cell lines express survivin proteins, which are located on the
mitotic phases and regulate mitotic progression. Survivin is
an inhibitor of apoptosis that is expressed in various human
cancer cells but is undetectable in most normal adult cells
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[35, 36]. Survivin has functions in both antiapoptosis and the
promotion of mitosis in cancer cells [36, 37]. e stability of
survivin is a result of the protein phosphorylation atr34 by
the mitotic kinase complex CDC2/cyclin B1 [38, 39]. In our
studies, baicalein reduced survivin protein expression (Figure
3(c)) and increased G2-M phase arrest at 8 h (Figure 9(c))
in CCRF-CEM cells. In addition, the percentage of G2-M
phase under combined treatment was more than baicalein or
vincristine monotherapy at 8 h, and the sub-G1 percentage
under combined treatment was greater than the sum of
that under each monotherapy at 24 h. Although the detailed
mechanism for the enhancement in therapeutic eﬃcacy in
combination therapy is unclear, this phenomenon might be
explained by that the simultaneous mitotic blocking stress
exerted on CCRF-CEM cells by baicalein and vincristine
tends to advance theMphase-arrested cells to enter apoptosis
earlier. Our data indicate that the combination of baicalein
and vincristine results in a synergistic therapeutic eﬃcacy.
More importantly, the use of baicalein in combination ther-
apy not only lowers the required dose of vincristine, thus
decreasing the related peripheral neuropathy, but baicalein
may also alleviate some common chemotherapeutic side
eﬀects, such as nausea, vomiting, diarrhea, and skin rashes.
is result was anticipated because baicalein is also used
in traditional Chinese medicine to treat nausea, vomiting,
diarrhea, stomach discomfort, and allergic and in�ammatory
conditions, such as arthritis, dermatitis, bronchitis, and
asthma.
However, the combined cytotoxic eﬀect of baicalein
with methotrexate (MTX) was not as good as with vin-
cristine (Supplementary Material available online at
http://dx.doi.org/10.1155/2013/124747). MTX is a folate
analogue designed to inhibit dihydrofolate reductase.
Reduced folate (tetrahydrofolate) is involved in the de novo
synthetic pathways for the purine and pyrimidine precursors
of DNA and RNA, which are required for cell proliferation;
thereby, MTX has been used extensively to treat neoplastic
diseases. Unlike baicalein, which is an M-phase blocker,
MTX is an S-phase inhibitor. Because the S phase was not
altered by baicalein in CCRF-CEM cells, the dispersed
cellular stress was less likely to advance the M phase- and
S phase-arrested cells to enter apoptosis earlier. erefore,
this combination is less likely to produce an enhanced
cytotoxic eﬀect. Despite the lack of enhanced cytotoxic eﬀect
when combined with MTX, baicalein still possesses many
bene�cial eﬀects, such as the alleviation of some common
chemotherapeutic side eﬀects (nausea, vomiting, diarrhea,
and skin rashes).
e enhanced therapeutic eﬀect of baicalein used in
combination with vincristine and the chemotherapeutic
side eﬀect-alleviating action of baicalein greatly enhance
the potential value of incorporating baicalein into future
treatment regimens for childhood ALL. Baicalein can be
introduced during the induction, intensi�cation and main-
tenance phases of childhood ALL treatment, and its anti-
in�ammatory actionmay also reduce the hepatotoxicity oen
observed during the maintenance phase of ALL treatment.
In conclusion, baicalein is a potential alternative drug
for treating childhood acute lymphocytic (lymphoblastic)
leukemia. Our results also support the use of combining
baicalein and vincristine to treat childhood ALL. However,
we also face a problem. Although to our knowledge, baicalein
is relatively safe and the optimum dose of baicalein has not
been established, we admit that 50 𝜇𝜇M of baicalein may not
be achievable under dietary conditions. Baicalein is easily
absorbed from the gastrointestinal tract of rats and undergoes
conversion to baicalein via a �rst pass glucuronidation
process in the liver [40, 41]. Baicalin is a glucuronated form
of baicalein, both of which have been shown to promote
anti-angiogenic eﬀects in vitro [42], inhibit the proliferation
of prostate cancer cells, and induce cell death via apoptosis
[43, 44]. Although 50𝜇𝜇Mof baicaleinmight not be achievable
under dietary conditions, this concentration is achievable
via intravenous administration. It will be more suitable for
baicalein to be administered intravenously in combination
chemotherapy. In fact, several baicalein studies have been
conducted by iv injection at doses of 10∼20mg/kg [45, 46]
which corresponds to about 60∼120 𝜇𝜇M. A recent study
by Tsai et al. has reported much improved stability of
baicalein by intravenous injection aer incorporation into
nanostructured lipid carriers (NLCs). e plasma level of
baicalein in NLCs was much higher and the half-life much
longer than those in the free control [47]. By virtue of NLC
technology, the feasibility of the use of intravenous baicalein
in combination chemotherapy in the future is substantially
enhanced.
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